Your browser doesn't support javascript.
loading
Gut microbiota regulates blood-cerebrospinal fluid barrier function and Aß pathology.
Xie, Junhua; Bruggeman, Arnout; De Nolf, Clint; Vandendriessche, Charysse; Van Imschoot, Griet; Van Wonterghem, Elien; Vereecke, Lars; Vandenbroucke, Roosmarijn E.
Afiliação
  • Xie J; VIB Center for Inflammation Research, Ghent, Belgium.
  • Bruggeman A; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
  • De Nolf C; VIB Center for Inflammation Research, Ghent, Belgium.
  • Vandendriessche C; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
  • Van Imschoot G; Department of Neurology, Ghent University Hospital, Ghent, Belgium.
  • Van Wonterghem E; VIB Center for Inflammation Research, Ghent, Belgium.
  • Vereecke L; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
  • Vandenbroucke RE; Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
EMBO J ; 42(17): e111515, 2023 09 04.
Article em En | MEDLINE | ID: mdl-37427561
ABSTRACT
Accumulating evidence indicates that gut microbiota dysbiosis is associated with increased blood-brain barrier (BBB) permeability and contributes to Alzheimer's disease (AD) pathogenesis. In contrast, the influence of gut microbiota on the blood-cerebrospinal fluid (CSF) barrier has not yet been studied. Here, we report that mice lacking gut microbiota display increased blood-CSF barrier permeability associated with disorganized tight junctions (TJs), which can be rescued by recolonization with gut microbiota or supplementation with short-chain fatty acids (SCFAs). Our data reveal that gut microbiota is important not only for the establishment but also for the maintenance of a tight barrier. Also, we report that the vagus nerve plays an important role in this process and that SCFAs can independently tighten the barrier. Administration of SCFAs in AppNL-G-F mice improved the subcellular localization of TJs at the blood-CSF barrier, reduced the ß-amyloid (Aß) burden, and affected microglial phenotype. Altogether, our results suggest that modulating the microbiota and administering SCFAs might have therapeutic potential in AD via blood-CSF barrier tightening and maintaining microglial activity and Aß clearance.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Microbiota / Microbioma Gastrointestinal Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Microbiota / Microbioma Gastrointestinal Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article